IDEXX Laboratories, Inc. (IDXX) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
IDEXX Laboratories, Inc. (IDXX) scores 8.2 out of 10 as of , computed from its reported financial statements. That reads as high quality. The reading rests on profitability, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge IDEXX Laboratories, Inc. yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
As of October 19, 2026, IDEXX Laboratories, Inc. scores 8.2 out of 10 on the Lemma Quality Score, a reading of high quality. Businesses in this band tend to combine good returns with a sound balance sheet, even if one pillar lags the others. Nothing in it comes from the share price or from forecasts: it is IDEXX Laboratories, Inc.’s own reported numbers, scored pillar by pillar.
Ranked with the 212 Healthcare companies Lemma publishes, the score sits at the 99th percentile, in the top tenth of its peers. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves IDEXX Laboratories, Inc. well above the median.
On profitability, IDEXX Laboratories, Inc. scores 9.4, a strong reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well above them, at the 99th percentile. Returns and margins at this level leave room to reinvest, absorb a bad year or return cash to shareholders without straining the business.
Solvency scores 9.1 out of 10, which reads as strong. The median across 150 Healthcare companies is 6.5, so IDEXX Laboratories, Inc. is well above its peers on this pillar and ranks at the 81st percentile. Strong solvency points to a balance sheet that can carry its debts comfortably, with interest well covered and little pressure from creditors.
Growth scores 6.1 out of 10, which reads as average. The median across 107 Healthcare companies is 4.9, so IDEXX Laboratories, Inc. is above its peers on this pillar and ranks at the 64th percentile. Average growth reflects a business expanding at roughly the pace of its sector, without a clear acceleration or decline.
Efficiency scores 8.4 out of 10, which reads as strong. The median across 200 Healthcare companies is 6.0, so IDEXX Laboratories, Inc. is well above its peers on this pillar and ranks at the 85th percentile. A strong efficiency reading usually shows up as healthy cash conversion: reported profit arriving as real cash rather than staying on the balance sheet.
Predictability scores 7.9 out of 10, which reads as strong. The median across 207 Healthcare companies is 3.4, so IDEXX Laboratories, Inc. is well above its peers on this pillar and ranks at the 94th percentile. High predictability means the company’s results have moved steadily from year to year, which makes the other pillars more trustworthy as a guide.
Profitability at 9.4 is IDEXX Laboratories, Inc.’s best pillar and growth at 6.1 its weakest. The 3.3 point gap between them is worth keeping in mind when reading the overall. A profitability lead usually reflects something durable in the business model rather than a good year. Slow growth limits how fast the business can compound, even when everything else is in order.
IDEXX Laboratories, Inc. has no pillar below the median of Healthcare companies, which leaves little room to rise. Its exposure is to slippage instead, and profitability carries the most weight: one point less there would mean an overall of roughly 7.9 rather than 8.2. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and IDEXX Laboratories, Inc. has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to IDEXX Laboratories, Inc. by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading IDEXX Laboratories, Inc. scores 8.2 out of 10, which reads as high quality. Its strongest pillar is profitability, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
IDEXX Laboratories, Inc. ranks at the 99th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against IDEXX Laboratories, Inc.’s 8.2.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for IDXX are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card